Alnylam and Roche have announced that their investigational RNA interference drug that targets angiotensinogen reduced patients’ mean systolic blood pressure. Patients in the zilebesiran arms of the ...

"Our study builds on the discovery of RNA interference, for which the Nobel Prize in Medicine was awarded in 2006. While siRNA therapies have already been used for genetic diseases, our work is the ...

Persons with mixed hyperlipidemia are at risk for atherosclerotic cardiovascular disease due to an elevated non–high-density lipoprotein (HDL) cholesterol level, which is driven by remnant cholesterol ...

ST. LOUIS – Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of ...